Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7% Following Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price shot up 7% during trading on Friday after TD Cowen raised their price target on the stock from $202.00 to $306.00. TD Cowen currently has a buy rating on the stock. Krystal Biotech traded as high as $261.54 and last traded at $266.3250. 38,914 shares traded hands during trading, a decline of 86% from the average session volume of 270,878 shares. The stock had previously closed at $248.91.

Several other research firms have also issued reports on KRYS. Chardan Capital increased their price target on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Citigroup upgraded Krystal Biotech from a “neutral” rating to a “buy” rating and lifted their price target for the company from $198.00 to $309.00 in a research note on Tuesday. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. HC Wainwright restated a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday. Finally, Zacks Research upgraded Krystal Biotech from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and a consensus price target of $260.50.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.70% of the stock is currently owned by insiders.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares during the period. United Services Automobile Association bought a new position in Krystal Biotech during the 1st quarter worth $305,000. Finally, Empowered Funds LLC bought a new position in Krystal Biotech during the 1st quarter worth $218,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

The stock has a 50-day moving average price of $227.55 and a 200-day moving average price of $182.63. The company has a market capitalization of $7.58 billion, a P/E ratio of 39.19 and a beta of 0.46.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The business had revenue of $97.80 million during the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.